ABBV$208.99
$208.88
Chart
Performance
Key Stats
AI ABBV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAbbVie exhibits strong fundamental performance with consistent profitability and a solid balance sheet, supported by a stable dividend. While growth rates might be moderate, the company benefits from its established product portfolio and strategic positioning in the biopharmaceutical sector. Technical indicators are mixed, suggesting a consolidation period before potential further upside. It's a good candidate for investors seeking stability and income within the healthcare sector.
Thematic
AbbVie operates within the large and growing biopharmaceutical sector, benefiting from demographic trends such as aging populations and increased healthcare spending. However, it faces intense competition and regulatory scrutiny inherent to the industry. The company's focus on immunology, neuroscience, and oncology aligns with key healthcare themes.
Fundamental
AbbVie demonstrates robust financial health with strong profitability, consistent revenue, and a manageable debt level. The company has a history of growing its dividend, making it attractive for income-seeking investors. Its P/E ratio is elevated but justifiable given its market position and profitability metrics.
Technical
The stock is trading within a range, with price action indicating neither strong bullish nor bearish momentum. Key moving averages suggest a neutral to slightly bearish short-term trend, while oscillators are mixed, pointing to a period of indecision.
| Factor | Score |
|---|---|
| Aging Population & Chronic Diseases | 85 |
| Biopharmaceutical Innovation | 70 |
| Healthcare Cost & Regulation | 40 |
| Emerging Markets Growth | 60 |
| Patent Expirations & Competition | 55 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 75 |
| Growth | 40 |
| Balance Sheet Health | 60 |
| Cash Flow | 90 |
| Dividends | 88 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 55 |
| Volume Confirmation | 60 |
| Support & Resistance | 65 |
| Key Price Levels | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
AbbVie has consistently exceeded earnings per share (EPS) estimates in recent quarters. For example, in Q2 2025, reported EPS of $2.46 beat the estimate of $2.38 by 3.16%.
Growing Dividend with Reasonable Yield
AbbVie offers a dividend yield of 3.34% (based on the latest data, actual yield may vary with price fluctuations). The company has a history of increasing its dividend payments, as seen in the increasing 'last_payment' amounts over time, suggesting a commitment to shareholder returns.
Bearish Points (7)
High Price-to-Earnings (P/E) Ratio
AbbVie's P/E ratio (TTM) of 81.55 is significantly higher than the broader market averages, suggesting that the stock may be overvalued relative to its current earnings. This could lead to a price correction if earnings growth falters.
Slowing Revenue and Net Income Growth
While revenue for 2024 is projected at $56.33 billion, the net income for Q4 2024 was a negative $22 million, indicating potential profitability challenges in the most recent period, and a significant drop from prior periods' net margins.
Calendar
July 2025
15
Ex-Dividend Date
July 2025
31
Next Earnings Date
H: $3.19
A: $2.91
L: $2.82
H: 15.21B
A: 15.03B
L: 14.80B
August 2025
15
Next Dividend Date
Profile
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Seasonals
Price Target
209.16 USD
The 39 analysts offering 1 year price forecasts for ABBV have a max estimate of 250.00 and a min estimate of 170.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor across multiple therapeutic areas including immunology (e.g., Taltz, Omvoh), neuroscience (migraine, Alzheimer's pipeline), and diabetes; significant R&D spend and strong pipeline.
Weight: 95
Diversified healthcare giant with a strong pharmaceutical segment, significant competitor in immunology (e.g., Stelara) and oncology; broad large-cap pharma peer.
Weight: 90
Key competitor in immunology (e.g., Enbrel) and oncology; strong presence in biosimilars and therapeutic proteins.
Weight: 88
Significant competitor in oncology (e.g., Opdivo, Yervoy) and immunology (e.g., Zeposia); diversified large pharmaceutical company.